Sign in Subscribe
Securities law

BiomX Inc. Announces Clinical Hold on Phase 2b Study for Cystic Fibrosis Drug Candidate

Strategic Insights

— 2 min read

BiomX Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company's Phase 2b study for its drug candidate BX004 in treating Cystic Fibrosis (CF). The FDA has raised concerns regarding a third-party nebulizer used in the study to deliver BX004 and has requested additional data from the Company. The clinical hold has paused patient screening and enrollment in the U.S. portion of the study, while enrollment and dosing of patients in Europe continue under the protocol of the study. The Company has submitted additional data to address the FDA's concerns and is awaiting a response. This announcement highlights the challenges and uncertainties associated with the development of new pharmaceuticals, particularly in the field of CF, where researchers are working to find effective treatments for this complex and debilitating disease.

Key Takeaways:

  • BiomX Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission announcing a clinical hold on its Phase 2b study for its drug candidate BX004 in treating Cystic Fibrosis.
  • The clinical hold was imposed by the FDA due to concerns regarding a third-party nebulizer used in the study to deliver BX004.
  • The Company has submitted additional data to address the FDA's concerns and is awaiting a response.
  • Patient screening and enrollment in the U.S. portion of the study have been paused due to the clinical hold.
  • Enrollment and dosing of patients in Europe continue under the protocol of the study.
  • The Company's ability to overcome the clinical hold and complete the study will be critical to the development of BX004 as a treatment for CF.
  • The FDA's decision to place a clinical hold on the study can have significant implications for BiomX Inc.'s regulatory and financial plans, as well as its relationships with investors and stakeholders.

Statistics:

  • The FDA has raised concerns regarding a third-party nebulizer used in the study to deliver BX004.
  • The Company has submitted additional data to address the FDA's concerns, including data on the nebulizer and its safety profile.
  • The clinical hold has paused patient screening and enrollment in the U.S. portion of the study, while enrollment and dosing of patients in Europe continue under the protocol of the study.
  • The Company's Phase 2b study is designed to test the efficacy and safety of BX004 in treating Cystic Fibrosis.

Sources:

  • BiomX Inc. (2025, August 19). Form 8-K: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549.
  • BiomX Inc. (2025, March 25). Annual Report on Form 10-K: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549.

Read more